4T1 is a mouse breast cancer cell line (of stage IV human equivalent) and is a 6-thioguanine resistant cell line selected from the 410.4 tumor without mutagen treatment. It is a highly tumorigenic model that is grown in BALB/c mice and presents adverse toxicity when continuously dosed with anti-PD-1 and anti-PD-L1, as reported in literature(1). It is still one of the most commonly used models for the assessment of novel anti-cancer immunotherapies. At CrownBio, the 4T1 model is offered as subcutaneous (flank) and orthotopic (mammary fat pad) models. In addition, a firefly luciferase tagged reporter line of 4T1 model is available, fascilitating disease monitoring via bioluminescent imaging.
|Cancer Type||Breast Cancer|
Response to Immune Checkpoint Inhibitors
(1) Mall C, Sckisel G.D., Proia D.A., Mirsoian A, Grossenbacher S.K., et al., Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenoeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology. 5(2), e1075114, 2016.